A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19600 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von B Halioua und 7 weiteren Autor:innen. Beteiligte Einrichtung: Private, Dermatologist, Paris, France. Hauptthemen laut MEDLINE: Betamethasone, Calcitriol, Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MC2 Therapeutics.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Private, Dermatologist, Paris, France.
- Almirall, Paris, France.
- EMMA, Patients Priority, Fontenay Sous-Bois, France.
- Department of Dermatology, Barts Health NHS Trust & Queen Mary University, London, UK.
- MC2 Therapeutics, A/S, Hørsholm, Denmark.
- University of Southern California, Los Angeles, San Francisco, California, USA.
Förderung
- MC2 Therapeutics
Zitieren
APA
Halioua, B., Caillet, G., Taieb, C., Bewley, A., Snel-Prentø, A., Praestegaard, M., Armstrong, A., & Pinter, A. (2024). A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19600
Vancouver
Halioua B, Caillet G, Taieb C, Bewley A, Snel-Prentø A, Praestegaard M, et al. A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19600
BibTeX
@article{Halioua2024,
author = {Halioua, B and Caillet, G and Taieb, C and Bewley, A and Snel-Prentø, A and Praestegaard, M and Armstrong, A and Pinter, A},
title = {A novel calcipotriol and betamethasone dipropionate ( CAL / BDP ) PAD ‐cream demonstrates greater improvements in daily activities and personal relationships than CAL / BDP gel/ TS : A post‐hoc analysis of DLQI outcomes from two phase 3 placebo‐controlled randomized clinical trials in mild‐to‐moderate psoriasis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19600}
}
EUVIMED